AUS
NZ
UK
CA
USA
IND
Highlights:
-
Bio-Path Holdings has launched a new therapeutic program for BP1001-A, targeting obesity and related metabolic diseases, marking a novel application of their DNAbilize® technology.
-
Enrollment is complete for the third dosing cohort in the Phase 1/1b clinical trial of BP1002, focusing on refractory/relapsed acute myeloid leukemia (AML), including patients resistant to venetoclax.
-
The company plans to commence preclinical studies for BP1001-A in Q4 2024, aiming to address insulin resistance.
Bio-Path Holdings {NASDAQ: BPTH} has announced two significant advancements in its research and development efforts. The company has initiated a therapeutic program aimed at developing BP1001-A for the treatment of obesity and related metabolic diseases. This represents the first non-cancer application of Bio-Path's proprietary DNAbilize® technology, showcasing the versatility of their platform.
Additionally, Bio-Path has completed enrollment for the third dosing cohort in its ongoing Phase 1/1b clinical trial evaluating BP1002 in patients with refractory/relapsed acute myeloid leukemia (AML), which includes those resistant to venetoclax. This rapid enrollment reflects the urgent need for innovative treatment options in the AML patient population.
Looking ahead, Bio-Path anticipates beginning preclinical studies for BP1001-A in the fourth quarter of 2024, with a focus on targeting insulin resistance. These developments signify important steps forward for the company as it seeks to expand its therapeutic offerings beyond oncology and address pressing health challenges in metabolic diseases and hematological malignancies.
